This webinar will present European initiatives working to make antisense oligonucleotide (ASO) therapies available for patients with rare diseases. Experts from different countries will share how they are organizing the development, coordination, and access to these personalized treatments. The session will end with a clinical example showing how an individualized ASO therapy was developed and used in practice.
Sign up now: https://events.teams.microsoft.com/event/f1b16619-1fde-4c34-be42-9c7400854c32@2461c129-d44f-406d-a778-d1a3c4c1527c
Date: 15 December 2026
Time: 5:00 pm – 6:30 pm CET
- Chair: Pr. Laurence Faivre
- Germany / Netherlands – N1C and 1M1M initiatives (Holm Graessner)
- Reino Unido – The Rare Therapies Launchpad: a pilot program for individualized medicines in the UK (Dan O’Connor)
- Spain – The Spanish Network for Personalized RNA Therapies (Miguel Ángel Rubio Pérez)
- France – The AnDDI-ASO network (Alban Ziegler)
- We would end with a clinical example illustrating the development of an ASO therapy:Antisense oligonucleotide treatment in a preterm infant with early-onset SCN2A developmental and epileptic encephalopathy (Matias Wagner)